Pyng Medical Corp.

TSX VENTURE : PYT


Pyng Medical Corp.

January 13, 2014 13:17 ET

Pyng Medical Signs Nine New Medical Device Distributors

Distributors to Market Pyng's Trauma and Resuscitation Products to the United States Civilian Market

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 13, 2014) - Pyng Medical Corp. (TSX VENTURE:PYT), an award-winning developer of trauma and resuscitation products for emergency, combat and critical care personnel, announces the signing of nine new distributors. Each distributor will market one or more of Pyng's three new products to the pre-hospital and hospital markets:

  • FASTResponder™ Sternal Intraosseous (IO) Device
  • T-PODResponder™ Pelvic Stabilization Device
  • MATResponder™ Tourniquet (launching Spring 2014)

"Pyng has been very successful in providing intraosseous, pelvic stabilization and tourniquet solutions to military personnel for well over a decade. Now, we've completely customized and launched new solutions to meet the needs of pre-hospital and hospital personnel as well," explains Mark Hodge, President and CEO of Pyng. "These nine new distributors we've brought on board have deep experience marketing medical devices to these target markets and will enable Pyng to more quickly get our new devices into the hands of such emergency and critical care personnel."

The company believes that these new distributors will enable it to gain further civilian-side market penetration than it has in the past, within most regions of the United States. The new distributors were specifically selected based upon their experience marketing medical devices to the pre-hospital and hospital markets, their complementary and non-competitive product portfolio, and their established relationships with emergency medical services and critical care hospital customers.

About Pyng Medical Corp.

For more than 20 years, Pyng Medical Corp. has been engineering and marketing award-winning trauma and resuscitation products for front-line critical care personnel world-wide. Pyng's product portfolio includes innovative sternal intraosseous(sternal IO), pelvic stabilization and tourniquet devices specifically designed and customized for both the military and civilian markets. With growing markets in North America, Europe and Asia, Pyng develops user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

More information about Pyng is available on SEDAR at www.sedar.com under the Company's profile and on its website: www.pyng.com.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Contact Information

  • Pyng Medical Corp.
    George Dorin
    Chief Financial Officer
    (604) 303-7964 x219
    www.pyng.com